我们是否应该将Olaparib"推进"到转移性割抵抗性前列腺癌?
David J VanderWeele1, Maha Hussain1
1Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago.
NEJM evidence
|February 6, 2024
概括
聚氨酸二酸) 聚合酶 (PARP) 抑制剂在治疗转移性割抵抗性前列腺癌 (mCRPC) 中表现有前途. 将PARP抑制剂与雄激素受体抑制剂结合起来,可能会使更广泛的患者群体受益,尽管结果在不同研究中有所不同.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 是一种具有挑战性的疾病.
- 聚氨酸二酸) 聚合酶 (PARP) 抑制剂在具有同源重组修复 (HRR) 缺陷的mCRPC中有效.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
